Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Up 0.8% - Still a Buy?

Key Points

• Armata Pharmaceuticals' stock increased by 0.8% to $2.55, with trading volume significantly up by 26% compared to the average session.
• Wall Street analysts raised the price target for Armata from $7.00 to $9.00 and issued a "buy" rating.
• Institutional investors, including GSB Wealth Management LLC, now hold about 3.57% of Armata Pharmaceuticals' shares, with a recent acquisition of 30,000 shares valued at approximately $57,000.

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) traded up 0.8% during mid-day trading on Friday . The stock traded as high as $2.60 and last traded at $2.55. 11,410 shares were traded during trading, an increase of 26% from the average session volume of 9,032 shares. The stock had previously closed at $2.53.

Analyst Ratings Changes

Separately, HC Wainwright upped their price objective on Armata Pharmaceuticals from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Monday, May 19th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Armata Pharmaceuticals currently has a consensus rating of "Buy" and an average target price of $9.00.

Armata Pharmaceuticals Trading Down 1.0%

The company has a market cap of $93.58 million, a price-to-earnings ratio of -2.50 and a beta of 0.99. The stock has a fifty day moving average price of $2.24.

Hedge Funds Weigh In On Armata Pharmaceuticals

A hedge fund recently bought a new stake in Armata Pharmaceuticals stock. GSB Wealth Management LLC bought a new stake in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 30,000 shares of the company's stock, valued at approximately $57,000. GSB Wealth Management LLC owned about 0.08% of Armata Pharmaceuticals at the end of the most recent quarter. 3.57% of the stock is owned by hedge funds and other institutional investors.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.